ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,131.82
0.58%
Dow Jones
43,486.73
0.18%
Gold vs US Dollar
2,664.365
0.45%
Brent Oil
73.625
1.08%
Bitcoin
96,729.47
2.58%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Novavax Inc (NVAX)

  7. Novavax Inc (NVAX) News

Novavax (NVAX)

Novavax Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NVAX
DateTimeSourceHeadlineSymbolCompany
15/11/202412:47PR Newswire (US)Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4)NASDAQ:NVAXNovavax Inc
13/11/202421:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NVAXNovavax Inc
13/11/202413:00PR Newswire (US)Novavax to Participate in Jefferies London Healthcare ConferenceNASDAQ:NVAXNovavax Inc
12/11/202421:08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NVAXNovavax Inc
12/11/202416:21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NVAXNovavax Inc
12/11/202413:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NVAXNovavax Inc
12/11/202413:02PR Newswire (US)Novavax Reports Third Quarter 2024 Financial Results and Operational HighlightsNASDAQ:NVAXNovavax Inc
11/11/202413:30PR Newswire (US)U.S. FDA Removes Clinical Hold on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 TrialNASDAQ:NVAXNovavax Inc
05/11/202422:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NVAXNovavax Inc
04/11/202421:30PR Newswire (US)Novavax to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Operational Highlights on November 12, 2024NASDAQ:NVAXNovavax Inc
04/11/202411:00PR Newswire (US)Åsa Manelius Named Managing Director of Novavax AB SiteNASDAQ:NVAXNovavax Inc
16/10/202412:14PR Newswire (US)Update on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 TrialNASDAQ:NVAXNovavax Inc
16/10/202412:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NVAXNovavax Inc
09/10/202411:00PR Newswire (US)Novavax's Updated 2024-2025 Nuvaxovid™ COVID-19 Vaccine Receives Authorization in the EUNASDAQ:NVAXNovavax Inc
25/09/202412:00PR Newswire (US)Novavax Names Dr. Ruxandra Draghia-Akli as New Executive Vice President and Head of Research & DevelopmentNASDAQ:NVAXNovavax Inc
18/09/202420:08Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NVAXNovavax Inc
13/09/202413:25PR Newswire (US)Novavax 2024-2025 Formula COVID-19 Vaccine Available at Major Pharmacies Across the U.S.NASDAQ:NVAXNovavax Inc
04/09/202413:25PR Newswire (US)Novavax to Participate in Upcoming September ConferencesNASDAQ:NVAXNovavax Inc
30/08/202420:19PR Newswire (US)Novavax 2024-2025 Formula COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S.NASDAQ:NVAXNovavax Inc
30/08/202419:46PR Newswire (US)Novavax 2024-2025 Formula COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S.NASDAQ:NVAXNovavax Inc
21/08/202420:47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NVAXNovavax Inc
20/08/202421:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NVAXNovavax Inc
08/08/202420:15Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:NVAXNovavax Inc
08/08/202412:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NVAXNovavax Inc
08/08/202412:02PR Newswire (US)Novavax Reports Second Quarter 2024 Financial Results and Operational HighlightsNASDAQ:NVAXNovavax Inc
08/08/202411:37Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NVAXNovavax Inc
08/08/202409:55IH Market NewsU.S. Index Futures Drop, Signaling Ongoing Market Volatility; Oil Prices StallNASDAQ:NVAXNovavax Inc
01/08/202413:25PR Newswire (US)Novavax to Host Conference Call to Discuss Second Quarter 2024 Financial Results and Operational Highlights on August 8, 2024NASDAQ:NVAXNovavax Inc
31/07/202409:55IH Market NewsASML Rises 7% on Export Waiver; Intel Plans Layoffs, HSBC $3B Buyback Announced, and MoreNASDAQ:NVAXNovavax Inc
02/07/202412:30PR Newswire (Canada)Novavax Submits Application to Health Canada for Updated Protein-based 2024-2025 Formula COVID-19 VaccineNASDAQ:NVAXNovavax Inc
 Showing the most relevant articles for your search:NASDAQ:NVAX

Your Recent History

TSXV
AEC.WT
Anfield Energy
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved

    BLACK FRIDAY

    ADVFN

    Celebrating 25 years Est 1999-2024

    Save up to 60%* for Level 2 Lite

    1 year 40%, 2 years 50% and *3 years 60%
    EU Flag

    *Across 3 years £2132.64 only £853.06